Advances in Clinical Toxicology Testing, An Issue of the Clinics in Laboratory Medicine

Practical Considerations for Implementing Immunoassays for Urine Drug Testing in Clinical Laboratories<br>Practical Considerations for Implementing Targeted Mass Spectrometry for Urine Drug Testing in Clinical Laboratories<br>Untargeted Mass Spectrometry Applications for Clinical Toxicology<br>Advances in Chromatography-Free and Ambient Ionization Mass Spectrometry Techniques Toward Clinical Toxicology Testing<br>Point-of-Care Drug Testing<br>Automated Quality Assurance Rules for Liquid Chromatography–Mass Spectrometry Testing in a Clinical Laboratory<br>Value of Improving Result Interpretation in Direct-to-Definitive Urine Drug Panels<br>Reflexive Drug Testing Strategies for Efficient Utilization of Resources and Better Interpretation<br>Interpreting Toxicology Results in Perinatal and Newborn Specimens: Urine, Meconium, and Umbilical Cord<br>Specimen Validity Testing in the Toxicology Laboratory<br>Detecting Xylazine: Prevalence, Pharmacokinetics, and Analytical Considerations<br>Detection of Fentanyl and Fentanyl Analogs<br>Testing Strategies and the Emergence of Designer Benzodiazepines<br>Recent Advances in Therapeutic Drug Monitoring of Antineoplastic and Antimicrobial Agents in Children<br>Optimizing Therapeutic Drug Monitoring of Anti-infectives: Patient and Clinical Setting Considerations<br>Pediatric Toxicology: Children Are Not Small Adults<br>Alcohol and Drug Testing in Motor Vehicle Crashes